Taking together the above work demonstrating the value of PI3K/AKT/mTOR, NF-κB, and STAT3 pathway inhibition in breast cancer, and the failure of some single pathway inhibitors in clinical trials, a strong basis is provided to support the simultaneous targeting of multiple pathways by CME for the treatment of TNBC. The gene discussed is AKT1; the disease is breast carcinoma.